- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
2
0 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
2 companies
Galderma Group
Market Cap: CHF 30.3b
Operates as a dermatology company worldwide.
GALD
CHF 127.50
7D
-4.6%
1Y
87.9%
Tecan Group
Market Cap: CHF 2.1b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 162.00
7D
-2.5%
1Y
-48.0%